News
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...
13d
Scripps News on MSNHHS, NIH announce development of universal vaccine for COVID-19 and influenzaResearchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...
The Food and Drug Administration announced Tuesday it has picked a new head of its center charged with vaccine approvals ... speed up the development of vaccines during the COVID-19 pandemic.
6d
News-Medical.Net on MSNOxford study reveals how COVID-19 vaccines prevent severe illnessA landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
9d
Zacks Investment Research on MSNModerna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...
R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...
Rudman Spergel, MD, director of clinical development at Moderna ... the technology to create one of the world’s first COVID-19 vaccines. In 2023, the company announced results from a phase ...
Trump halted biological research funding to adversaries such as China and Iran because of concerns COVID-19 originated in a ...
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results